Hutchinson Institute for Cancer Outcomes Research

Publications

Adverse Events Associated with Bevacizumab and Chemotherapy in Older Patients with Metastatic Colorectal Cancer, Clin Colorectal Cancer. 2012 Dec 28. [Epub ahead of print], Shankaran V, Mummy D, Koepl L, Blough D, Yim YM, Yu E, Ramsey S.

Referral and Treatment Patterns Among Patients With Stages III and IV Non-Small-Cell Lung Cancer, J Oncol Pract. 2013 Jan;9(1):42-50. doi: 10.1200/JOP.2012.000640, Goulart BH, Reyes CM, Fedorenko CR, Mummy DG, Satram-Hoang S, Koepl LM, Blough DK, Ramsey SD.

Risk factors for financial hardship in patients receiving adjuvant chemotherapy for colon cancer: a population-based exploratory analysis, J Clin Oncol. 2012 May 10;30(14):1608-14. doi: 10.1200/JCO.2011.37.9511. Epub 2012 Mar 12, Shankaran V, Jolly S, Blough D, Ramsey SD.

Value-of-Information Analysis within a Stakeholder-Driven Research Prioritization Process in a US Setting: An Application in Cancer Genomics, Med Decis Making. 2013 May;33(4):463-71. doi: 10.1177/0272989X13484388, Carlson JJ, Thariani R, Roth J, Gralow J, Henry NL, Esmail L, Deverka P, Ramsey SD, Baker L, Veenstra DL.

Facilitating comparative effectiveness research in cancer genomics: evaluating stakeholder perceptions of the engagement process, J Comp Eff Res. 2012 Jul;1(4):359-370, Deverka PA, Lavallee DC, Desai PJ, Armstrong J, Gorman M, Hole-Curry L, O'Leary J, Ruffner B, Watkins J, Veenstra DL, Baker LH, Unger JM, Ramsey SD.

Getting our priorities straight: a novel framework for stakeholder-informed prioritization of cancer genomics research, Genet Med. 2013 Feb;15(2):115-22. doi: 10.1038/gim.2012.103. Epub 2012 Oct 4, Esmail LC, Roth J, Rangarao S, Carlson JJ, Thariani R, Ramsey SD, Veenstra DL, Deverka P.

The value of comparative effectiveness research: projected return on investment of the RxPONDER trial (SWOG S1007), Contemp Clin Trials. 2012 Nov;33(6):1117-23. doi: 10.1016/j.cct.2012.08.006. Epub 2012 Aug 18, Wong WB, Ramsey SD, Barlow WE, Garrison LP Jr, Veenstra DL.

Lung cancer screening with low-dose computed tomography: costs, national expenditures, and cost-effectiveness, J Natl Compr Canc Netw. 2012 Feb;10(2):267-75, Goulart BH, Bensink ME, Mummy DG, Ramsey SD.

How comparative effectiveness research can help advance 'personalized medicine' in cancer treatment, Health Aff (Millwood). 2011 Dec;30(12):2259-68. doi: 10.1377/hlthaff.2010.0637, Ramsey SD, Veenstra D, Tunis SR, Garrison L, Crowley JJ, Baker LH.

Provider and partner interactions in the treatment decision-making process for newly diagnosed localized prostate cancer, BJU Int. 2011 Sep;108(6):851-6; discussion 856-7. doi: 10.1111/j.1464-410X.2010.09945.x. Epub 2011 Jan 18, Zeliadt SB, Penson DF, Moinpour CM, Blough DK, Fedorenko CR, Hall IJ, Smith JL, Ekwueme DU, Thompson IM, Keane TE, Ramsey SD.

Costs and cost effectiveness of a health care provider-directed intervention to promote colorectal cancer screening, J Clin Oncol. 2009 Nov 10;27(32):5370-5. doi: 10.1200/JCO.2008.20.6458. Epub 2009 Oct 13, Shankaran V, Luu TH, Nonzee N, Richey E, McKoy JM, Graff Zivin J, Ashford A, Lantigua R, Frucht H, Scoppettone M, Bennett CL, Sheinfeld Gorin S.

Costs and cost-effectiveness of a low-intensity patient-directed intervention to promote colorectal cancer screening, J Clin Oncol. 2007 Nov 20;25(33):5248-53, Shankaran V, McKoy JM, Dandade N, Nonzee N, Tigue CA, Bennett CL, Denberg TD.